特发性肺纤维化的诊疗工具:血液生物标志物的潜力与挑战  

Diagnostic and therapeutic tools for idiopathic pulmonary fibrosis:the potential and challenges of blood biomarkers

作　　者：阮红霞 陈捷[1] Ruan Hongxia;Chen Jie(Department of Laboratory Medicine,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院实验医学科,成都610041

出　　处：《中华检验医学杂志》2024年第10期1115-1122,共8页Chinese Journal of Laboratory Medicine

摘　　要：特发性肺纤维化(IPF)是肺纤维化最常见的形式,是一种以进展快、不可逆、预后差为主要特点的慢性进行性间质性肺疾病,确诊的患者其中位生存期仅为3~5年,因此,及时的诊断和准确的评估对控制疾病、改善患者结局、延长生存年限至关重要。临床上诊断IPF的主要方法包括临床评估、影像学检查以及病理活检,但因其主要依赖于医生的临床经验、有创以及操作烦琐等因素,在临床实践中仍存在一定的困难。随着医学的高速发展,近年来与IPF发病机制密切相关的血液生物标志物不断被发现,这为IPF的临床实验室诊断、鉴别诊断、预后及疗效评估方法的建立提供了重要参考和依据。Idiopathic pulmonary fibrosis(IPF),the most common form of pulmonary fibrosis,is a chronic progressive interstitial lung disease characterized by rapid progression,irreversibility,and poor prognosis.The median survival of diagnosed patients is only 3 to 5 years,so timely diagnosis and accurate evaluation are essential for controlling the disease,improving patient outcomes,and prolonging survival years.The main methods of diagnosing IPF in clinical practice include clinical evaluation,imaging examination,and pathological biopsy.However,there are still challenges in clinical application as they rely heavily on the clinical expertise of physicians,involve invasive procedures,and can be cumbersome.The rapid development of medicine has led to the discovery of various blood biomarkers closely associated with the pathogenesis of IPF.These biomarkers are crucial reference and foundation for establishing clinical laboratory diagnosis,differential diagnosis,prognosis,and efficacy assessment methods for IPF.

关 键 词：肺纤维化 生物标志物 血液 临床应用 

分 类 号：R563[医药卫生—呼吸系统]